Do we have a novel treatment approach to avoid re-thoracotomies?
- Cardiac Surgery
INTERNATIONAL EXPERTS MEETING
Optimizing patient management with CytoSorb Hemoperfusion Therapy in Cardiac Surgery – Scientific evidence and clinical practice
Reduce bleeding complications in Ticagrelor and Rivaroxaban treated patients undergoing emergency Cardiac Surgery
Chair: Prof. Michael Schmoeckel, Hamburg/Germany
Do we have a novel treatment approach to avoid re-thoracotomies?
Dr. Nikola Bradic, Zagreb/Croatia
Play Video
Share
|
Do we have a novel treatment approach to avoid re-thoracotomies?
Share
|
INTERNATIONAL EXPERTS MEETING
Optimizing patient management with CytoSorb Hemoperfusion Therapy in Cardiac Surgery – Scientific evidence and clinical practice
Reduce bleeding complications in Ticagrelor and Rivaroxaban treated patients undergoing emergency Cardiac Surgery
Chair: Prof. Michael Schmoeckel, Hamburg/Germany
Do we have a novel treatment approach to avoid re-thoracotomies?
Dr. Nikola Bradic, Zagreb/Croatia
More Videos
Welcome & Introduction | Stefan Baudis | Webinar 1 | 2021
How bleeding complications and costs can be reduced? | Stephan Geidel | Webinar 1 | 2021
Jak można ograniczyć powikłania krwotoczne i koszty? | Stephan Geidel | With Polish Voice Over
Do we have a novel treatment approach to avoid re-thoracotomies? | Nikola Bradic | Webinar 1 | 2021
Why is it relevant? | Robert F Storey | Webinar 1 | 2021